Prevalence of Powassan Virus Seropositivity Among People with History of Lyme Disease and Non-Lyme Community Controls in the Northeastern United States.

Autor:	Kapoor T; Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA., Murray L; Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York, USA., Kuvaldina M; Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York, USA., Jiang CS; Department of Hospital Biostatistics, The Rockefeller University, New York, New York, USA., Peace AA; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA., Agudelo M; Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA., Jurado A; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA., Robbiani DF; Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA., Klemens O; Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany., Lattwein E; Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany., Sabalza M; EUROIMMUN US, Mountain Lakes, New Jersey, USA., Fallon BA; Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York, USA., MacDonald MR; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.
Jazyk:	angličtina
Zdroj:	Vector borne and zoonotic diseases (Larchmont, N.Y.) [Vector Borne Zoonotic Dis] 2024 Apr; Vol. 24 (4), pp. 226-236. Date of Electronic Publication: 2024 Mar 01.
DOI:	10.1089/vbz.2022.0030
Abstrakt:	Introduction: Lyme disease (LD) affects ∼476,000 people each year in the United States. Symptoms are variable and include rash and flu-like symptoms. Reasons for the wide variation in disease outcomes are unknown. Powassan virus (POWV) is a tick-borne flavivirus that causes disease ranging from asymptomatic infection to encephalitis, neurologic damage, and death. POWV and LD geographic case distributions overlap, with Ixodes species ticks as the common vectors. Clinical ramifications of coinfection or sequential infection are unknown. Objectives: This study's primary objective was to determine the prevalence of POWV-reactive antibodies in sera samples collected from previously studied cohorts of individuals with self-reported LD history residing in the Northeastern United States. As a secondary objective, we studied clinical differences between people with self-reported LD history and low versus high POWV antibody levels. Methods: We used an enzyme-linked immunosorbent assay (ELISA) to quantify IgG directed at the POWV envelope (E) protein domain III in 538 samples from individuals with self-reported LD history and 16 community controls. The samples were also tested with an ELISA assay to quantify IgG directed at the POWV NS1 protein. Results: The percentage of individuals with LD history and possible evidence of POWV exposure varied depending on the assay utilized. We found no significant difference in clinical symptoms between those with low or high POWV IgG levels in the in-house assay. Congruence of the EDIII and NS1 assays was low with only 12% of those positive in the in-house EDIII ELISA testing positive in the POWV NS1 ELISA. Conclusions: The results highlight the difficulty in flavivirus diagnostic testing, particularly in the retrospective detection of flavivirus exposure. The findings suggest that a prospective study with symptomatic patients using approved clinical testing is necessary to address the incidence and clinical implications of LD and POWV co-infection or sequential infection.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu